• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.

作者信息

Peragine Nadia, De Propris Maria Stefania, Intoppa Stefania, Milani Maria Laura, Mariglia Paola, Mauro Francesca Romana, Raponi Sara, Soddu Stefano, Cuneo Antonio, Rigolin Gian Matteo, Del Giudice Ilaria, Foà Robin, Guarini Anna

机构信息

Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.

Italian Group for Adult Hematologic Diseases (GIMEMA) Foundation, Rome.

出版信息

Haematologica. 2020 Oct 5;106(5):1500-1503. doi: 10.3324/haematol.2020.262071.

DOI:10.3324/haematol.2020.262071
PMID:33054124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8094098/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8964/8094098/40d847d9c223/1061500.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8964/8094098/a31c2b4b0381/1061500.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8964/8094098/7bd3079c992b/1061500.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8964/8094098/40d847d9c223/1061500.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8964/8094098/a31c2b4b0381/1061500.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8964/8094098/7bd3079c992b/1061500.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8964/8094098/40d847d9c223/1061500.fig3.jpg

相似文献

1
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.黏附、迁移和激活分子的表达调控可能预测接受依鲁替尼加利妥昔单抗治疗的慢性淋巴细胞白血病患者的反应程度。
Haematologica. 2020 Oct 5;106(5):1500-1503. doi: 10.3324/haematol.2020.262071.
2
Ibrutinib and rituximab for chronic lymphocytic leukaemia.依鲁替尼和利妥昔单抗治疗慢性淋巴细胞白血病
Lancet Oncol. 2019 Sep;20(9):e471. doi: 10.1016/S1470-2045(19)30528-5. Epub 2019 Aug 8.
3
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.依鲁替尼和利妥昔单抗治疗与B细胞慢性淋巴细胞白血病相关的副肿瘤性天疱疮
Intern Med. 2018 Aug 15;57(16):2395-2398. doi: 10.2169/internalmedicine.0578-17. Epub 2018 Mar 9.
4
[Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].维奈托克联合利妥昔单抗治疗对伊布替尼耐药的慢性淋巴细胞白血病患者：一例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):700-702. doi: 10.3760/cma.j.issn.0253-2727.2019.08.018.
5
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?FCR方案有治愈一部分慢性淋巴细胞白血病患者的潜力吗？
Clin Adv Hematol Oncol. 2019 Apr;17(4):214-216.
6
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.依鲁替尼和利妥昔单抗治疗的不适合的慢性淋巴细胞白血病患者的复杂核型：GIMEMA LLC1114 2期研究
Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.
7
Combo Therapy Effective for Relapsed CLL.联合疗法对复发慢性淋巴细胞白血病有效。
Cancer Discov. 2015 Jul;5(7):OF8. doi: 10.1158/2159-8290.CD-NB2015-081. Epub 2015 Jun 1.
8
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).idelalisib联合利妥昔单抗与伊布替尼治疗复发/难治性慢性淋巴细胞白血病的疗效相当：波兰成人白血病组（PALG）的一项回顾性病例匹配研究
Anticancer Res. 2018 May;38(5):3025-3030. doi: 10.21873/anticanres.12557.
9
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
10
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.伊布替尼联合苯达莫司汀和利妥昔单抗对比安慰剂、苯达莫司汀和利妥昔单抗治疗既往治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤（HELIOS）：一项随机、双盲、III 期研究。
Lancet Oncol. 2016 Feb;17(2):200-211. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5.

引用本文的文献

1
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.伊布替尼耐药慢性淋巴细胞白血病中克隆内增殖亚群的早期再现。
Leukemia. 2024 Aug;38(8):1712-1721. doi: 10.1038/s41375-024-02301-y. Epub 2024 Jun 24.
2
The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia.微环境和细胞粘附分子在慢性淋巴细胞白血病中的作用
Cancers (Basel). 2023 Oct 26;15(21):5160. doi: 10.3390/cancers15215160.
3
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.

本文引用的文献

1
L-Selectin Expression is Influenced by Phosphatase Activity in Chronic Lymphocytic Leukemia.L-选择素表达受慢性淋巴细胞白血病中磷酸酶活性的影响。
Cytometry B Clin Cytom. 2019 Mar;96(2):149-157. doi: 10.1002/cyto.b.21771. Epub 2019 Feb 6.
2
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.随机对照试验：伊布替尼对比伊布替尼联合利妥昔单抗治疗慢性淋巴细胞白血病患者。
Blood. 2019 Mar 7;133(10):1011-1019. doi: 10.1182/blood-2018-10-879429. Epub 2018 Dec 7.
3
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
CD49d 表达鉴定出慢性淋巴细胞白血病的一个具有不同生物学特性的亚型，这种亚型在接受 BTK 抑制剂治疗时无进展生存期更差。
Clin Cancer Res. 2023 Sep 15;29(18):3612-3621. doi: 10.1158/1078-0432.CCR-22-3217.
4
Sialylation regulates migration in chronic lymphocytic leukemia.唾液酸化调节慢性淋巴细胞白血病中的迁移。
Haematologica. 2023 Jul 1;108(7):1851-1860. doi: 10.3324/haematol.2022.281999.
5
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.功能检测鉴定和分层慢性淋巴细胞白血病中 PI3K 抑制剂的反应。
Clin Cancer Res. 2022 Oct 14;28(20):4444-4455. doi: 10.1158/1078-0432.CCR-22-1221.
6
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.一线伊布替尼与利妥昔单抗联合治疗的疗效及治疗中断对不适合接受治疗的慢性淋巴细胞白血病患者的影响：Gimema LLC1114研究结果
Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.
解析 TP53 突变慢性淋巴细胞白血病对伊布替尼治疗反应不佳的原因。
Br J Haematol. 2019 Feb;184(3):392-396. doi: 10.1111/bjh.15613. Epub 2018 Oct 18.
4
In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.与高 CD49d 相反，低 CXCR4 表达表明慢性淋巴细胞白血病 (CLL) 细胞依赖于微环境。
Ann Hematol. 2018 Nov;97(11):2145-2152. doi: 10.1007/s00277-018-3410-x. Epub 2018 Jun 28.
5
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.伊布替尼单药治疗初治和复发/难治性慢性淋巴细胞白血病：5 年经验。
Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2.
6
Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.依鲁替尼和idelalisib可阻断与慢性淋巴细胞白血病（CLL）细胞在肿瘤微环境中的黏附和激活相关的免疫表型变化。
Leuk Lymphoma. 2018 Aug;59(8):1927-1937. doi: 10.1080/10428194.2017.1403598. Epub 2017 Nov 22.
7
BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.布鲁顿酪氨酸激酶（BTK）抑制导致慢性淋巴细胞白血病中CXCR4趋化因子受体的表面表达、信号传导及功能受损。
Leukemia. 2016 Apr;30(4):833-43. doi: 10.1038/leu.2015.316. Epub 2015 Nov 9.
8
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.靶向肿瘤性B细胞并利用微环境：依鲁替尼和idelalisib的“双面性”
J Hematol Oncol. 2015 May 29;8:60. doi: 10.1186/s13045-015-0157-x.
9
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.在慢性淋巴细胞白血病患者中，使用布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼治疗期间，12号染色体三体与淋巴细胞再分布缩短相关。
Br J Haematol. 2015 Jul;170(1):125-8. doi: 10.1111/bjh.13269. Epub 2014 Dec 18.
10
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.伊布替尼联合利妥昔单抗治疗高危慢性淋巴细胞白血病患者的安全性与活性：一项单臂2期研究
Lancet Oncol. 2014 Sep;15(10):1090-9. doi: 10.1016/S1470-2045(14)70335-3. Epub 2014 Aug 20.